Why AbbVie Is a No-Brainer Stock to Buy on the Dip

By Leo Sun – Apr 16, 2026 at 3:41PM ESTKey PointsAbbVie’s stock pulled back from its record highs.It’s still reasonably valued, and it pays an attractive dividend.AbbVie's (ABBV +0.27%) stock closed at a record high of $238.71 on Oct. 1, 2025. However, its stock has pulled back by about 13% since then. Let's see why that pullback represents a golden buying opportunity for long-term investors who can tune out the near-term noise. Image source: Getty Images. Why did AbbVie's stock decline? Before its recent pullback, AbbVie's stock had doubled in value over the previous four years. That rally was mainly driven by the market's enthusiasm for its two newer immunology drugs, Skyrizi and Rinvoq, to replace the revenue lost from its former blockbuster, Humira. ExpandNYSE: ABBVAbbVieToday's Change(0.27%) $0.57Current Price$208.99Key Data PointsMarket Cap$369BDay's Range$206.52 - $209.6652wk Range$168.54 - $244.81Volume5.1MAvg Vol7.1MGross Margin70.12%Dividend Yield4.02% However, the market was also pricing in much of that future growth and assuming that Skyrizi and Rinvoq wouldn't face any significant regulatory or competitive headwinds. The bullish thesis also assumed its Humira sales wouldn't wither too quickly before those catalysts kicked in. As the macro headwinds intensified over the past few months, some of AbbVie's investors likely noticed those issues and took some money off the table. Expectations for elevated interest rates, rather than continued rate cuts, also weighed on high-yield dividend stocks like AbbVie. But if we look beyond those near-term issues, AbbVie is still a rock-solid dividend stock with a forward yield of 3.3%. From 2025 to 2028, analysts expect its EPS to rise more than fivefold as its new drug sales surge, yet it looks reasonably valued at 24 times this year's earnings. So if you're looking for a safe place to park your cash in this turbulent market, AbbVie checks all the right boxes.Read NextApr 15, 2026 •By Jason HallDividend Kings of 2026Apr 15, 2026 •By David Jagielski, CPA3 High-Yielding Dividend Stocks to Buy, Even If You're Worried About the MarketApr 14, 2026 •By Prosper Junior BakinyCould AbbVie Crash Lilly's Weight‑Loss Party?Apr 13, 2026 •By Eric VolkmanS&P 500 Index Dividend Yields Are Teasing All-Time Lows. Here Are 3 Dividend Darlings That Crush This Trend.Apr 8, 2026 •By David Jagielski, CPA3 Absurdly Cheap Dividend Stocks to Buy in April 2026Apr 7, 2026 •By Thomas NielThis Pharma Dividend Has Been Raised Every Single Year for Over a DecadeAbout the AuthorLeo Sun is a contributing Motley Fool stock market analyst who has worked with the company since 2013, covering technology, consumer goods, industrial, and financial sectors. He became a self-made millionaire by age 40 through long-term investing, crediting lessons from Warren Buffett and Peter Lynch. Leo is a regular guest on CNBC Asia providing stock analysis on Chinese technology companies, including Tencent, Baidu, and Alibaba. He previously wrote for InvestorGuide and holds a bachelor’s degree in English from the University of Texas at Austin.TMFSunLionX@TMFSunLionStocks MentionedAbbVieNYSE: ABBV$208.99(+0.27%)+$0.57*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.